Cardiometabolic Disease and COVID-19: Risk, Treatment and Trials
Published: 13 July 2020
In this series, Mikhail Kosiborod and Hertzel Gerstein discuss the effects of Covid-19 and metabolic disease, early treatment with metabolic therapies and the Phase III DARE-19 Trial looking at dapagliflozin in Covid-19 patients.
Recorded remotely from Hamilton and Kansas City, 2020.
The Effect of COVID and Metabolic Disease and Early Treatment
Metabolic Therapy Treatments
Phase III DARE-19 Trial
Dr Kosiborod is an internationally recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, and quality care and outcomes.
He is a cardiologist, Vice President of Research at Saint Luke's Health System, Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City.
Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.
Hertzel C Gerstein
Dr Hertzel C Gerstein is an Endocrinologist and Professor at McMaster University and Hamilton Health Sciences, where he holds the Population Health Institute Chair in Diabetes Research.